Gastroenterology Research and Practice / 2015 / Article / Tab 3

Clinical Study

Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study

Table 3

Characteristics of patients with vascular events during follow-up.

VariablePatients with vascular events
( = 7)
Patients without vascular events
( = 83)

Age (years), median (IQR) 47 (31–62)50 (40–62)
Males, (%)4 (57.1%)43 (51.8%)
Personal history VTE, (%)1 (14.3%)6 (7.2%)
Family history VTE, (%)1 (14.3%)7 (8.4%)
Unprovoked SVT, (%)2 (28.6%)31 (37.4%)
Liver cirrhosis, (%)3 (42.9%)11 (13.3%)
Solid cancer, (%)0 (0%)6 (7.2%)
Myeloproliferative neoplasm, (%)1 (14.3%)6 (7.2%)
Recent abdominal surgery, (%)0 (0%)10 (12.1%)
Hormonal therapy, (%1 (33.3%)10 (25.0%)
Inflammatory bowel disease, (%)0 (0%)5 (6.0%)
JAK2 V617F mutation, (%1 (20.0%)2 (5.4%)
Factor V Leiden or prothrombin G20210A mutation, (%1 (20.0%)8 (16.0%)
Previous VKA treatment duration (months), median (IQR)9.9 (3.2–12.9)12.7 (7.2–24.0)
Time within therapeutic range (%), median (IQR)68 (67–80)62 (56–75)
Antiplatelet therapy during follow-up, (%)2 (28.6%)12 (14.5%)

Percentage calculated on the female population.
Percentage calculated on the number of tested patients.
IQR = interquartile range, SVT = splanchnic vein thrombosis, VKA = vitamin K antagonist, and VTE = venous thromboembolism.